ReviewHealthcare (Basel, Switzerland)2022

Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Yu Na Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.